Dr. Caroline Baumal appointed chief medical officer of Apellis Pharmaceuticals

Retina specialist Caroline Baumal, MD, has been appointed the chief medical officer of Apellis Pharmaceuticals. 

Advertisement

Dr. Baumal will replace Federico Grossi, MD, who will remain with the company through Feb. 28, according to a Jan. 5 release. The two will work together through the transition and prepare for the prospective launch of pegcetacoplan for geographic atrophy.

Dr. Baumal currently serves as a professor of ophthalmology at New England Eye Center, part of Tufts Medical Center in Boston, where she specializes in diseases and surgery of the retina and vitreous.

She has been awarded a variety of honors for her work in ophthalmology, including the senior achievement award from the American Academy of Ophthalmology and the lifetime achievement award from the Vit-Buckle Society.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Unlocking Structural Heart Capacity: How Leading Programs Use EMR and Data to Improve Patient Flow and Throughput

Wednesday, August 19
11:00 AM - 12:00 PM CDT

Presenters: Katie Kennedy, MSN, APRN, NP-C, Community Heart and VascularMisty Theriot, BSN, RN, CPHQ, FACC, Lake Charles Memorial Health SystemKatie Worthington, DNP, RN, Atlantic Health SystemTaryn Shipley, MBA, CSSBB, Lean HealthTech

Advertisement

Next Up in Ophthalmology

  • East Lansing-based Michigan Surgical Center has disclosed a data breach that may have exposed personal information, according to a July…

  • Cincinnati-based MidWest Eye Center welcomed Alec Bradley, MD, an ophthalmologist who specializes in premium cataract surgery, refractive surgery, microinvasive glaucoma…

Advertisement

Comments are closed.